Samra Sanni

Samra Sanni has worked in the pharmaceutical and biotechnology industries since 2009. Samra began as a Research Assistant at Glostrup Hospital in 2009, and then became a Ph.D. student at Glostrup Hospital and Novo Nordisk in 2010. From 2015 to 2019, they worked as a Senior Scientist in Obesity Biology and Research Scientist in Incretin Biology at Novo Nordisk. In 2019, they moved to Antag Therapeutics as Director of In vitro pharmacology. In 2020, they joined Bainan Biotech in the same role. Currently, they are Vice President of Drug Research at ResoTher Pharma ApS.

Samra Sanni has a diverse educational background. Samra completed a Bachelor of Science (BSc) in Medicinal and Pharmaceutical Chemistry at Aarhus University from 2003 to 2006. Samra then went on to earn a Master's degree in Human Biology at Københavns Universitet - University of Copenhagen from 2007 to 2009. Following this, they earned a Doctor of Philosophy (Ph.D.) in Molecular Pharmacology from Københavns Universitet - University of Copenhagen from 2010 to 2015. Most recently, they completed a Business administration (HD1) at Copenhagen Business School from 2018 to 2020.